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Phenolic compounds of Iris adriatica and their 
antimycobacterial effects
Little is known about the pharmacological acti-
vities of Iris adriatica (Iridaceae), a plant endemic 
to Dalmatia (Croatia). We therefore performed a 
bioassay-guided fractionation including high-
performance counter current chromatography 
(HPCCC) and antibacterial tests using Mycobac-
terium smegmatis mc² 155. One obtained fraction 
was found to be antimycobacterially active with 
a MIC of 64 mg L–1. Furthermore, fractions were 
tested for resistance modulatory effects using 
ethidium bromide as substrate. We were able to 
identify the pure isoflavonic compounds irigenin 
and irilone and a fraction containing mainly 
benzophenone 2,4,6-trihydroxy-4-methoxy-benzo-
phenone, responsible for the resistance-modula-
tory activity of this plant. 
Keywords: Iris adriatica, Radix Iridis, phenolic 
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Iris adriatica Trinajstić ex Mitić (Iridaceae) is a rhizomatous plant endemic to Croatia, 
restricted to the broader central Dalmatian region. The plant is characterized by a dwarf 
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habit and yellow or violet solitary flowers. I. adriatica is listed as one of about 350 species 
of the genus Iris, where it is considered as one of the smallest species in this genus (1, 2). I. 
adriatica has not been researched extensively and therefore limited data is available. Rhi-
zomes of Iris species were traditionally used in European medicine as expectorant, stimu-
lant, diuretic, emetic drugs and supplements in toothpowders. Also, a specialty for teeth-
ing children, Rhizoma Iridis pro infantibus, is reported, which consists of long pieces of 
rhizomes that are chewed for pain relief (3). In Traditional Chinese Medicine, the mixture 
“She-gan” including Iris species is used against cough and pharyngitis (4). Furthermore, a 
variety of activities against cancer, inflammation, hyperlipidemia and neurodegenerative 
diseases are reported for various Iris species (5, 6). The postulated toxicity of Iris, causing 
diarrhea, nausea and skin irritations (7), is not documented in literature for I. adriatica. 
Iridin and myristic acid are mentioned as irritant substances that can be found at high 
concentrations in rhizomes of plants of this genus (7).
Thus far, over 30 compounds have been isolated and identified from the rhizomes of 
I. adriatica (8, 9). A detailed metabolic profiling of phenolic compounds of the rhizomes of 
native populations of I. adriatica was recently published by our group (8). Mainly phenolic 
compounds such as isoflavones are found in large numbers and quantities, followed by 
xanthones and benzophenones. Representing the most abundant substance group, ger-
manaism B was found as the leading isoflavone. Irilone, another found isoflavone was 
reported to be antidiabetically active by inhibiting α-amylase and to be of phytoestro-
genic nature when used in combination with red clover (10, 11). Concerning xanthones, 
mangiferin and irisxanthone are heading the list (8). In literature, mangiferin is reported 
to possess analgesic, antidepressant, antidiabetic, antiinflammatory, antioxidant, antipro-
liferative, antiviral, diuretic and immunomodulatory properties (12, 13). Some isoflavones, 
namely, irigenin and irilone, were reported to be potent inhibitors of the cytochrome P450 
1A enzyme and to be of chemopreventive nature (3). At a glance, several pharmacologi-
cally promising activities were reported for compounds found in I. adriatica, but no anti-
bacterial data was reported for this species.
Developing resistance rates challenge health care systems and research worldwide. 
Due to the fact that bacteria have rapidly become resistant to antibiotics on the market, it 
is not surprising that the World Health Organization reports increasing numbers of resis-
tant tuberculosis (TB) being by now the leading cause of death caused by a single infec-
tious agent. In 2017, 82 % of all resistant TB cases were of multidrug-resistant manner (14). 
Therefore, new strategies to combat increasing resistance rates are urgently needed. One 
of the approaches to limit resistance development is the application of so called efflux 
pump inhibitors, which are able to block the outward transport of antibiotics from cells 
(15).  The boundless pool of plants in the world is still an insufficiently explored field for 
new antibacterials and efflux pump inhibitors. A continued study of Newman et al. has 
shown the high impact of plants as sources for new drugs (16). Therefore, exploitation of 
the so far unresearched plant material is of high importance to obtain new antibacterials 
for the fight against resistant microbes.
Antibacterial effect of Iris sp. was already detected against Escherichia coli, Pseudomo-
nas aeruginosa, Salmonella typhi and Staphylococcus aureus (17). Interestingly, in that study it 
was found that Proteus vulgaris seems to be resistant to extracts of five Iris species. The re-
ported antituberculotic activity of I. germanica leaves could not be confirmed by literature 
research, which only resulted in negative documentation against Mycobacterium tuberculo-
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sis (5). The aim of our study was to assess whether Iris adriatica is an antimycobacterial 
agent, which was facilitated by bioassay-guided fractionation. In addition to the already 
putative antiinflammatory, phytoestrogenic, antidiabetic and chemopreventive activities 
of compounds found in I. adriatica, we would like to shed light on the potential of this plant 
against mycobacteria.
EXPERIMENTAL
Plant material and extraction
Rhizomes of I. adriatica were collected at native sites in April 2016 (Table S1) and air-
dried for one month, followed by Soxhlet extraction of 261.5 g plant material with metha-
nol (extraction yield 16.3 %). As plant material of endemic I. adriatica from its original 
habitats was not available in large amounts, in this study we also included a pure com-
pound isolated from a commercial sample of Radix Iridis (which can include rhizomes 
originating from I. germanica, I. pallida or I. florentina (18), Kottas Pharma (Austria) based on 
the fact that this substance was also identified in I. adriatica (8).
Analysis of extracts, fractions and pure compounds by UHPLC-PDA-ESI-MS
Analysis was carried out according to a method recently published by our group (8). 
In short, a Dionex Ultimate 3000 RS LC system coupled to a LTQ XL linear ion-trap mass 
spectrometer equipped with an ESI ion source (all components Thermo Scientific) and a 
Zorbax SB-C18 Rapid Resolution HD column, 100 × 2.1 mm, 1.8 µm particle size (Agilent), 
were used. Elution with 0.1 % formic acid in water (A) and gradient grade acetonitrile (B) 
started with 8 % B, increasing to 45 % B 0–9 min; 9–13 min 45 % B to 100 % B; 13–15 min 
100 % B; 15–15.5 min 100 % B to 8 % B, equilibrating for 8 min at a flow rate of 0.39 mL 
min–1. Column temperature was set to 35 °C, injection volume was kept at 2 µL. PDA detec-
tion was performed in the wavelength range of 190 to 500 nm. Mass spectra were recorded 
in negative and positive ion modes in the m/z range of 50 to 2000 amu. (source voltage 3.5 kV 
(ESI pos), 5.0 kV (ESI neg); capillary temperature 300 °C; source temperature 350 °C; sheath 
gas flow 65 arb (arbitrary units), auxiliary gas flow 15 arb).
Fractionation and isolation of compounds from I. adriatica
Fractionation was carried out with vacuum column chromatography (CC) using silica 
gel 60 (Normasil 60; 0.040–0.063 mm VWR Chemicals) and solvents following the gradient: 
n-hexane/EtAc 80:20, n-hexane/EtAc 50:50, n-hexane/EtAc 0:100, methanol/EtAc 20:80, 
methanol/EtAc 35:65, methanol/EtAc 50:50, methanol/EtAc 100:0 and methanol/water 90:10 
(19). 20.2 g of crude methanolic extract was applied to 200 g of silica gel (resulting in 31 
fractions (F1–31). Obtained fractions were combined to 10 subfractions according to their 
thin layer chromatographic profile (TLC plates silica gel 60 F254, Merck, mobile phase tolu-
ene/ethyl formate/formic acid 5:4:1). Irilone was purified from F9–10 (representing subfrac-
tion 2, eluted with n-hexane/EtAc 0:100) by subsequent high-performance countercurrent 
chromatography (HPCCC) fractionation. Spectrum HPCCC (Dynamic Extractions Co. 
Ltd., Slough, Berkshire, UK) was equipped with analytical (22 mL, 0.8 mm i.d., 1 mL sample 
loop) and semipreparative (137 mL, 1.6 mm i.d., 6 mL sample loop) coils. The following 
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parameters were used: semi-preparative coil; rotation speed 1600 rpm, flow-rate 6 mL 
min–1; stationary phase – upper phase (reversed-phase mode or head-to-tail mode); tem-
perature 30 °C; detection wavelength 260 nm. For the HPCCC fractionation of F9–10 (100 
mg), a two-phase solvent system composed of n-hexane/EtAc/2-propanol/methanol/water 
(5:6:2:3.5:6, V/V) was used to get pure irilone (6.6 mg) in 38–42 min. Additional HPCCC 
fractionation of F9–10 (60 mg) with n-hexane/EtAc-2-propanol/methanol/water (5:6:3:3.5:6, 
V/V) led to F-B (5.9 mg), a fraction rich in 2,4,6-trihydroxy-4-methoxy-benzophenone (ca. 
90 %) as verified by LC-PDA-ESI-MS analysis (8), in 25–26 min. 
Fractionation of F9–10 (100 mg) was also carried out by open column chromatography 
using Sephadex LH-20 as stationary phase (column 2 × 45 cm), while EtAc and methanol 
(9:1, V/V) served as eluents. Obtained fractions were merged to 6 fractions, from which 
sub-fractions were collected using semipreparative reversed phase (C18) high performance 
liquid chromatography. Semipreparative HPLC was carried out on a Shimadzu system 
(CBM-20A controller, LC-20AT solvent delivery module, SIL-10AF autosampler, CTO-20AC 
column oven, SPD-M20A diode array detector, FRC-10A fraction collector) using a Luna 
C18(2), 250 × 10 mm, 10 µm column (Phenomenex). One fraction, designated as F-IT, was 
obtained by elution with water:methanol (45:55) with a flow rate of 4 ml min–1 between 16 
and 17.7 min by structure elucidation using NMR (see Table S2); it was found to be a mix-
ture of iristectorigenin A (major amount) and irigenin to a smaller extent (ratio ca. 80:20). 
This fraction was also tested against mycobacteria in order to draw conclusions on struc-
ture-activity relationships.
Fractionation and isolation of compounds from Radix Iridis
In UHPLC-PDA-MS analysis, it became obvious that irigenin was present in much 
larger amounts in a commercial sample of Radix Iridis (see Fig. S1); hence, this material 
was used for isolation of this isoflavonoid. An ethanolic Soxhlet extract of Radix Iridis was 
prepared by extracting 300 g of powdered plant material with ethanol (96 %) for 4 h to yield 
31.1 g extract (10.4 % extraction yield). After pre-fractionation by vacuum CC on silica 
(Normasil 60; 0.040–0.063 mm VWR Chemicals) with a gradient as used for I. adriatica (see 
above), HPCCC fractionation of fraction C (100 mg, eluted with EtAc from the silica column) 
with n-hexane/EtAc/2-propanol/methanol/ (5:6:2:4.5:6, V/V) yielded pure irigenin (13.1 mg) 
in 16–19 min. This substance was also identified in I. adriatica and therefore subjected to 
antimycobacterial testing in order to gain an insight into the activities exerted by pure 
compounds.
Structures of isolated isoflavonoids were confirmed by NMR analysis (1H, 13C, HMBC, 
HSQC); data are presented in Table S2.
Antimycobacterial assays
Extracts, fractions and pure compounds were tested at an established minimum inhi bi-
tory concentration (MIC) and modulation factor (MF) assay against the strain Mycobacterium 
smegmatis mc² 155 (ATCC 700084) (20). MIC assay was carried out with the crude extract at 
the initial concentration of 512 mg L–1, whereas fractions were tested at 256 mg L–1 and pure 
compounds at 128 mg L–1. Testing agents were diluted in dimethyl sulfoxide prior to testing 
and added into 96-well plates in duplicate, serially diluted with Mueller Hinton Broth 
medium and incubated with a 5 × 105 cfu mL–1 bacterial inoculum for 72 hours at 37 °C 
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(n = 2). Isoniazid was added as a control substance to each plate for intra-plate monitoring 
and both sterile and growth control were performed on each plate. The same conditions 
were applied for the MF assay, whereby the testing concentration was set to ½ of the deter-
mined MIC. In our model, we standardly used ethidium bromide (EtBr) in order to reveal 
the resistance modifying effects based on efflux pump inhibition, since EtBr has been 
shown to be the substrate of many efflux pumps. The modulation factor clarifies the MIC 
reduction of the antibiotic in the presence of a modulator. The higher the MF, the lower is the 
amount of substance needed to exert the same antibacterial effect. All plates, independently 
of the assay, were evaluated with a colorimetric assay using MTT after 30 min of additional 
incubation.
RESULTS AND DISCUSSION
Analysis of the crude extracts, fractions and pure compounds obtained after isolation 
procedures was done by UHPLC-PDA-ESI-MSn as previously reported (8). Identification 
Fig. 1. UHPLC-PDA-ESI-MS analysis of the methanolic extract of Iris adriatica rhizomes. Base peak 
chromatogram ESI positive mode (top) and UV chromatogram at 290 nm (bottom). Compounds marked 
with numbers were found in fractions or isolated as pure compounds for antimycobacterial testing. 
1 = irisxanthone (in mixture with iristectorigenin A-O-trihexoside); 2 = iristectorigenin A-7-O-[b-d-
glucopyranosyl-(1®6)-b-d-glucopyranoside], in mixture with other isoflavonoids; 3 = germa naism E; 
4 = germanaism B; 5 = 2,4,6-trihydroxy-4-methoxy-benzophenone; 6 = iristectorigenin A; 7 = irigenin; 
8 = irilone; X = mixture of isoflavones (Mr = 312 (irisolone), 330, 360).
678
S. Ochensberger et al.: Phenolic compounds of Iris adriatica and their antimycobacterial effects, Acta Pharm. 69 (2019) 673–681.
 
was deduced from mass spectral fragments as well as UV data, in case of isolated com-
pounds finally confirmed by two dimensional NMR analysis. Figure 1 shows a representa-
tive ESI-MS base peak chromatogram (positive mode) and a UV chromatogram (290 nm) 
of the methanolic extract of I. adriatica rhizomes with the compounds relevant for our 
study on antimycobacterial activity.
Testing of the methanolic crude extract revealed no antimycobacterial effect against 
M. smegmatis. The modulation factor assay indicated a promising MF of 4 which means a 
4-fold reduction of MIC value of the testing agent (in our case EtBr) when used in combina-
tion with the modulator (plant extract/pure compound). This extract was therefore further 
separated to possibly assign a pure compound of particular antibacterial value. Except for 
fraction F9–10 with a MIC of 64 mg L–1, no antimycobacterial effect was documented for I. 
adriatica fractions. Also, pure compounds were not able to inhibit mycobacterial growth 
sufficiently when tested in the MIC assay. MF testing revealed F9–10, F11–14 and F15–18 as 
moderately active, resulting in a MF of 2. Regarding pure compounds, the fraction F-B 
(2,4,6-trihydroxy-4-methoxy-benzophenone), irigenin and irilone were found to be re-
sponsible for the resistance-modulatory activity of I. adriatica (Table I). Hence, the resis-
Table I. Antimycobacterial results of Iris adriatica extract, fractions and pure compounds against 
Mycobacterium smegmatis
Fraction/Substance MIC mg L–1 (µmol L–1) MFEtBr
Crude extract (MeOH) 512 4
F1-3 > 256 1
F4-6 > 256 1
F7-8 > 256 1
F9-10 64 2
F11-14 256 2
F15-18 > 256 2
F19-20 > 256 1
F21-24 > 256 1
F25-27 > 256 0.5
F28-31 > 256 0.5
F-B > 256 (983.71) 4
F-IT > 256 (775.08) 2
Irigenin 128 (355.25) 4
Irilone > 256 (858.34) 4
Isoniazid 4–8 (29.17–58.33) –
EtBr 8 (20.29) –
EtBr – ethidium bromide, F-B – fraction mainly containing 2,4,6-trihydroxy-4-methoxy-benzophenone, F-IT – frac-
tion largely containing iristectorigenin A and to a smaller extent irigenin, MeOH – methanol, MF – modulation 
factor, MIC – minimum inhibitory concentration, n = 2.
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tance modulatory effect of the crude methanolic extract of I. adriatica cannot be referred to 
a single compound but to the concerted action of at least three compounds; further interac-
tions with other extract components cannot be excluded. By comparing values of F-IT and 
irigenin it can be seen that irigenin is the most active component owing to the lower MF 
determined in the mixture with iristectorigenin A. For irigenin, cytotoxicity testing was 
performed using A549 and CaCo2 cells resulting in values of 22.57 µM and 39.88 µM, 
 respectively (21). Ehrlich’s ascites carcinoma cells were incubated with irilone and the 
compound was able to show cytotoxicity of 47.7 µM for MTT experiments (22). Fig. 2 shows 
the corresponding structural formulas of the essential pure compounds that were found 
to be active in I. adriatica, revealing diverse structural features, i.e., a highly methoxy-
lated isoflavone (irigenin), an isoflavone bearing a methylene dioxy residue (irilone) and a 
methoxy lated benzophenone; hence, no clear conclusions on structure activity relation-
ships can be drawn. Using LC-PDA-ESI-MS analysis (8), the following compounds were 
identified in fractions F19–20 and F21–24: germanaism B and irisxanthone (both fractions), 
iristectorigenin A-7-O-[b-d-glucopyranosyl-(1®6)-b-d-glucopyranoside] and germanaism 
E (only in F21–24). These compounds were not able to elicit any antimycobacterial or resis-
tance-modulatory activity. These results point to the conclusion that the glycoside of iris-
tectorigenin A (F21–24, MF of 1) is of less resistance-modulatory potency compared to 
aglycone (F-IT).
The results of irigenin and irilone are in line with those of biochanin A (genistein-4 -́
methyl ether), for which efflux-modulatory activity against M. smegmatis was previously 
reported (20). Pure compounds of I. adriatica are therefore promising candidates for subse-
quent studies. 
Fig. 2. Chemical structures of resistance-modulatory active compounds found in Iris adriatica tested 
against Mycobacterium smegmatis.
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CONCLUSIONS
We were able to identify two isoflavones and one benzophenone with resistance-modu-
latory activity in I. adriatica and thus provide the first evidence of this plant being an anti-
mycobacterial agent against fast-growing mycobacteria such as Mycobacterium smegmatis 
mc² 155. A follow-up study would be of interest to identify the antibacterial agent in F9–10, 
which is still unknown. In case of restricted availability of plant material from endemic 
Iris species, related commercial sources of other Iris species can be employed for extraction 
and isolation of pure compounds. HPCCC seems to be an excellent tool for this purpose, 
providing pure target compounds in sufficient amounts to further test them for their efflux 
pump-inhibitory potential, which in turn could be helpful as adjuvants in the therapy 
against resistant bacteria.
Acronyms, abbreviations, symbols. – EtAc – ethyl acetate, EtBr – ethidium bromide, MeOH – methanol, 
MF – modulation factor, MIC – minimum inhibitory concentration, MTT – thiazolyl blue tetrazolium 
bromide, TB – tuberculosis.
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